Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Mytrex Health Technologies's 3-Year RORE % for the quarter that ended in Dec. 2025 was -25.52%.
The industry rank for Mytrex Health Technologies's 3-Year RORE % or its related term are showing as below:
ROCO:4431's 3-Year RORE % is ranked worse than 73.77% of 2890
companies
in the Industrial Products industry
Industry Median: 5.185
vs ROCO:4431: -25.52
Mytrex Health Technologies (ROCO:4431) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Mytrex Health Technologies 3-Year RORE % Related Terms
Mytrex Health Technologies 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4431 vs GEV, ETN, PH: 3-Year RORE % Comparison
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies 3-Year RORE % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Mytrex Health Technologies (ROCO:4431) has a 3-Year RORE % of -25.52 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Mytrex Health Technologies and its competitors. According to the industry distribution chart, Mytrex Health Technologies ranks #2132 out of 2890 companies in the Industrial Products industry, placing it in the top 73.8%.
Is Mytrex Health Technologies' 3-Year RORE % too high?
Mytrex Health Technologies' current 3-Year RORE % is -25.52. Based on the distribution chart, Mytrex Health Technologies ranks #2132 out of 2890 companies in the Industrial Products industry, which is below the industry midpoint. Overall, Mytrex Health Technologies has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' 3-Year RORE % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #2132 out of 2890 companies for 3-Year RORE %. This places Mytrex Health Technologies in the lower half of its industry. The industry median 3-Year RORE % is 5.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for an Industrial Products company?
The median 3-Year RORE % among Industrial Products companies is 5.19, based on 2,890 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Mytrex Health Technologies and its competitors. For the Industrial Products industry, the median 3-Year RORE % is 5.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current 3-Year RORE % is -25.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$37.32, compared to a current price of NT$17.00 — trading 54.4% below its estimated fair value. The current 3-Year RORE % is -25.52. Mytrex Health Technologies' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current 3-Year RORE % is -25.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$17.00 is trading 54.4% below its estimated GF Value™ of NT$37.32.
GuruFocus considers Mytrex Health Technologies to be Significantly Undervalued.
Key valuation signals for ROCO:4431:
3-Year RORE %: -25.52
GF Value™: NT$37.32 vs. price of NT$17.00 (54.4% below fair value)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
63GF Score
Get the complete analysis for ROCO:4431
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
